Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review)

ANDREA LAMPIS1,2, MARGHERITA RATTI1,3, MICHELE GHIDINI4, MILKO B. MIRCHEV5, ALI FUAT OKUDUCU6, NICOLA VALERI1,2,7 and JENS CLAUS HAHNE1,2

1Division of Molecular Pathology, 2Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton SM25NG, UK; 3Medical Department, Division of Oncology, Hospital Trust of Cremona, I-26100 Cremona; 4Division of Medical Oncology, Hospital Policlinic ‘Fondazione IRCCS Ca’ Granda Ospedale Maggiore’, I-20122 Milan, Italy; 5Clinic of Gastroenterology, Medical University, 9002 Varna, Bulgaria; 6Pathology Langgasse, 3063 Bern, Switzerland; 7Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton SM25NG, UK

Received December 21, 2020; Accepted February 25, 2021

DOI: 10.3892/ijmm.2021.4930

Correspondence to: Dr Jens Claus Hahne, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton SM25NG, UK
E-mail: jens.hanhe@icr.ac.uk

Abstract. Oesophageal cancer is one of the most aggressive malignancies with limited treatment options, thus resulting in a high morbidity and mortality. With 5-year survival rates of only 5-10%, oesophageal cancer holds a dismal prognosis for patients. In order to improve overall survival, the early diagnosis and tools for patient stratification for personalized treatment are urgent needs. A minority of oesophageal cancers belong to the spectrum of Lynch syndrome-associated cancers and are characterized by microsatellite instability (MSI). Microsatellite instability is a consequence of defective mismatch repair protein functions and it has been well characterized in other gastrointestinal tumours, such as colorectal and gastric cancer. In the latter, high levels of MSI are associated with a better prognosis and with an increased benefit to immune-based therapies. Therefore, similar therapeutic approaches could offer an opportunity of treatment for oesophageal cancer patients with MSI. Apart from immune checkpoint inhibitors, other immunotherapies such as adoptive T-cell transfer, peptide vaccine and oncolytic viruses are under investigation in oesophageal cancer patients. In the present review, the rationale and current knowledge about immunotherapies in oesophageal cancer are summarised.

Key words: immunotherapy, oesophageal cancer, immune checkpoint inhibitors, adoptive T-cell therapy, peptide vaccine, oncolytic viruses

Contents
1. Introduction
2. Biological background of tumour immunotherapy
3. Immunotherapy in oesophageal cancer
4. Immune checkpoint inhibitors
5. Adoptive T-cell therapy
6. Peptide vaccine
7. Oncolytic viruses
8. Conclusion and perspectives

1. Introduction

The incidence of oesophageal cancer has rapidly increased over the past years and it is currently the fifth most common type of cancer worldwide with a very high mortality rate (1,2). Oesophageal cancer is subdivided into two groups according to its histological appearance: Oesophageal squamous cell carcinoma (predominant in western countries) and oesophageal adenocarcinoma (most common form in Asia) (3,4). Thus far, no molecular markers for prognosis or treatment efficacy have been discovered for squamous cell carcinoma. For oesophageal adenocarcinoma, the human epidermal growth factor receptor-2 (HER-2) status has been proven to be an efficient biomarker. HER-2 is scored by...
The identified main reasons for the high mortality rate of patients with oesophageal cancer are mainly the late stage of diagnosis (13) and the key role of tumour microenvironment in this type of cancer (27), where the surrounding stromal cells seem to exert an important influence in supporting tumour cell survival (27). Apart from cancer-associated fibroblasts, that are able to support tumour growth and metastasis by altering the extracellular matrix by secreting growth factors and cytokines, several immune cells [e.g., myeloid-derived suppressor cells, tumour-associated macrophages and regulatory T-cells (TREGs)] are involved in support the development of oesophageal cancer (27). Therapies targeting the tumour microenvironment and/or the immune system may thus be able to increase the survival of patients with oesophageal cancer. Over the past years, immunotherapy in particular has revolutionized the management and outcome of several types of cancer, such as melanoma, lung, gastric and kidney cancer (28). Therefore, it may be advantageous to explore the benefits from immunotherapy for oesophageal cancer. The identification and selection of robust biomarkers predicting clinical benefit are also mandatory before commencing immunotherapy treatment, as even though generally well-tolerated compared to standard therapies, immunotherapy is associated occasionally with severe toxic side-effects, such as cutaneous, gastrointestinal, endocrine and hepatic toxicity. Thus, only patients with oesophageal cancer who have the highest likelihood of benefit from immunotherapy should be offered this therapeutic regimen. For example, it is well-established that immune checkpoint inhibitors are particularly effective against mismatch repair-deficient tumours (29). In general, tumours with MSI have a higher mutation rate, which increases the probability for the immune system to recognize tumour cells (29-31). Recently, several reviews have summarized the current knowledge on immunotherapy and cancer (32-34). The present review focuses on the current state of the use of immunotherapy in oesophageal cancer.

2. Biological background of tumour immunotherapy

The immune system is a highly complex and specialised biological network including specific cells, protein and organs and is usually composed of two types: Adaptive (specific) and innate (non-specific) (35). In recognising and preventing the spread of cancer cells, the innate immunity components, such as natural killer (NK) cells, dendritic cells and macrophages are of pivotal importance; nevertheless, T-cells from the adaptive immune are recruited in order to track and kill tumour cells (35,36). Recently, a new model that provides a mechanistic explanation of this interaction termed 'cancer-immunity cycle' has been suggested (35). According to this model, dead cancer cells release antigens that in turn are recognised by antigen-presenting cells (particularly by dendritic cells). This results in the priming and activation of dendritic cells and T-cells in lymph nodes, followed by the recruitment of helper T-cells [cluster of differentiation (CD)4+ T-cells] and cytotoxic T-lymphocytes (CD8+ T-cells) at the tumour site. Following the infiltration of the tumour microenvironment, immune cells recognize and attack tumour cells that results in the release of further tumour antigens. The whole cancer-immunity cycle is fine-tuned by different stimulating and inhibitory factors, such as chemokines, cytokines, metabolic compounds, surface proteins and immune checkpoint receptors to prevent autoimmunity (37).

Cancer cells use different strategies to escape the immune system, and to capture and reprogram immune cells, leading to immune evasion. Among these strategies is the mechanisms of shedding of MHC class I chain-related protein A and B (MICA and MICB) from tumour cells into the tumour microenvironment as protection against NK cell-mediated killing (38-40). In addition, tumour cells express immune checkpoint proteins, such as programmed cell death 1 ligand 1 (PD-L1) and receptors, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on the surface, but also secrete exosomes which contains these immune checkpoint regulators. After binding to proteins expressed on the immune cells (T-cells, B-cells and myeloid cells) the checkpoint regulators exert an inhibitory signal and lead to the suppression of the immune response (41-43).

Furthermore, cancer cells, as well as tumour-associated macrophages are able to secrete chemokines, such as chemokine (C-C motif) ligand (CCL)-17 and CCL-22 which attract a subpopulation of T-cells, the so-called TREGs. TREGs are known to regulate and suppress the activity of other immune cells and to help preventing autoimmune reactions under healthy conditions (44,45). In tumour tissue, TREGs protect cancer cells and foster tumour growth (46,47). Moreover, CD8+ T-cells are inhibited directly by myeloid-derived suppressor cells (MDCs) which are stimulated by tumour-derived growth factors (48,49). In addition, stromal cells in the tumour microenvironment inhibit the function of the immune system further supporting tumour progression and metastasis (50).
3. Immunotherapy in oesophageal cancer

The immune system is a complex network of interacting cells and biochemical signals that orchestrate the recognition and attack of external antigens, whilst preventing autoimmune reactions. Under physiological conditions, this is guaranteed by a fine-tuned interplay between immune cells and a balance between stimulatory and inhibitory signals (51,52). Cancer cells often find a way to de-regulate the balanced immune system by manipulating signalling pathways to evade from immune surveillance. To overcome the mechanisms of tumour immune evasion and use the immune system as weapon against cancer, either agonists of stimulatory receptors or antagonists of inhibitory signals can be used (41). Nevertheless, according to currently available study results, only a subset of oesophageal cancer patients may benefit from immunotherapy (53). Therefore, there is an urgent need to identify biomarkers for the prediction of the benefit from immunotherapy, so that patients can be selected for treatment and those who have no benefit from immunotherapy are spared from side-effects (e.g., cutaneous, gastrointestinal, endocrine and hepatic toxicity) and therapy failure. In light of this scenario, currently, several clinical trials are underway to evaluate the efficacy of different immunotherapies combined with other treatment options in oesophageal cancer patients (Table I) with the aim to increase the therapeutic option for oesophageal cancer patients. The majority of these studies are ongoing Phase 2 studies and the results have not been published yet.

In the following section, the main immunotherapy approaches that have been studied thus far will be discussed (Fig. 1).

4. Immune checkpoint inhibitors

Immune checkpoints are of pivotal importance to prevent autoimmunity reactions by the inhibition of antigen recognition via T-cell receptors (TCRs) (41,54,55). Cancer cells use immune checkpoint proteins to inactivate the adaptive immune system by blocking tumour specific T-cells and escape from immune surveillance. Thus far, the immune checkpoint receptors programmed cell death protein 1 (PD-1; also known as CD279) and CTLA-4 (also known as CD152) have been found to be associated with the inhibition and downregulation of T-cell activity (41,54,55).

PD-1 receptor is highly expressed on T-cells, B-cells and NK cells. The ligand for PD-1 receptor is PD-L1 often also termed B7-homolog 1 (B7-H1) or CD274. This molecule is expressed in peripheral tissues following exposure to inflammatory cytokines and limits T-cell activity (56). Furthermore, interleukin (IL)-18, an inflammatory cytokine that accumulates in the tumour microenvironment, results in the upregulation of PD-L1 in activated mature NK cells and triggers immunosuppression (57). In melanoma, lung, breast, pancreatic, gastric, colon, ovarian and oesophageal cancers, PD-L1 is often found overexpressed on cancer cells (58). This enables tumour cells to interact with PD-1 receptors on T-cells and this interaction prevents T-cell activation, proliferation and ultimately leading to T-cell apoptosis (41).

The expression of CTLA-4 receptor is restricted to activated T-cells (e.g., TREGs), whereas the homolog CD28 is also expressed on non-activated T-cells. Ligands for both receptors are the immunoglobulin proteins B7-1 (CD80) and B7-2 (CD86), which are expressed early during the immune response on antigen-presenting cells, such as macrophages and dendritic cells or on B-cells and monocytes, respectively. CTLA-4 receptor has a higher affinity for ligands and competing with CD28 on ligand binding; the interaction between B7-1 or B7-2 with CD28 results in T-cell activation, whereas the interaction with CTLA-4 inhibits T-cell activation at an early stage (59,60).

It has been widely proven that PD-L1 expression is one of the key mechanisms through which several cancers evade the immune response; thus, it is not surprising that inhibitors of PD-L1 and PD-1 have been identified thus far as one of most efficient and broadly used immunotherapies for cancer (61-71). Recently, a monoclonal antibody targeting PD-1, pembrolizumab, has been approved for the treatment of oesophageal and oesophago-gastric junction adenocarcinoma by the US Food and Drug Administration (FDA) (8). The prerequisite for the treatment of oesophageal cancer with pembrolizumab is either a proven PD-L1 expression on the cancer cells and a high MSI, or a proven defective mismatch repair system. Therefore, most probably, the subgroup of Lynch syndrome-associated oesophageal cancers patients may benefit from this new treatment option. According to a previous study, it is possible to predict the efficacy of pembrolizumab in patients with oesophageal cancer by using a six-gene interferon-γ gene expression signature (72). This offers the possibility to stratify oesophageal cancer patients and limit the targeted treatment to the group that will most probably benefit from the anti-PD-L1 therapy.

Earlier in 2020, the FDA approved nivolumab, a fully human monoclonal antibody against PD-1 (73) for patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma as a second line following 5-fluorouracil- and platinum-based chemotherapy. The overall survival benefit is 2.5 months according to a phase 3 clinical study (74).

Currently, combination therapies with anti-PD1 and anti-CTLA-4 antibodies are forthcoming (75). According to the first preliminary results from clinical studies (NCT02743494, CheckMate 648 and CheckMate 649) the combination of nivolumab with the anti CDLA-4 antibody, ipilimumab, led to an improved clinical response in oesophageal cancer compared to treatment with nivolumab alone (76,77). The combination of nivolumab and ipilimumab appears to be safe; nevertheless, it must be considered that CTLA-4 blockade results in more severe and more common side-effects than it is the case for targeting PD-1/PD-L1 alone. Therefore, the development of novel strategies for reducing serious adverse side-effects is an urgent need and the first steps need to be carefully controlled (78).

As a potential biomarker for prediction of the response to immune checkpoint inhibitor therapy, the total amount of PD-1+ CD4+ T-cells in the tumour microenvironment is discussed. According to the presence or absence of CD4+ T-cells and PD-1 expression in the tumour microenvironment, a stratification of patients is possible. The absence of CD4+ T-cells and PD-1 expression results in immunological ignorance; in a situation where only one component (either CD4+ T-cells or PD-1)
Table I. Clinical trials investigating immunotherapeutic options in combination with other therapeutic options in oesophageal cancer patients.

| Immunotherapeutic option | Stage of development | Combined with | ClinicalTrials.gov identifier | Start time | Current status |
|--------------------------|----------------------|---------------|-------------------------------|------------|----------------|
| Nivolumab                | Phase 1/2            | Chemoradiotherapy | NCT03278626 | 2017 | Active, but not recruiting |
|                          | Chemoradiotherapy    | NCT03544736 | 2018 Recruiting |
|                          | Chemoradiotherapy +  | NCT03604991 | 2018 Recruiting |
|                          | Ipilimumab           |               |                 |
| Ipilimumab               | Phase 2              | Chemoradiotherapy +  | NCT03437200 | 2018 Recruiting |
|                          | Ipilimumab +         |               |                 |
|                          | Chemotherapy         | NCT3143153 | 2017 Recruiting |
| Relatlimab               | Phase 2              | Chemoradiotherapy +  | NCT03437200 | 2018 Recruiting |
|                          | Ipilimumab           |               |                 |
| Pembrolizumab            | Phase 2              | Chemoradiotherapy | NCT03416244 | 2018 Recruiting |
|                          | Chemotherapy         | NCT03914443 | 2019 Recruiting |
|                          | After chemotherapy   | NCT02569242 | 2015 Active, but not recruiting |
|                          | After chemoradiotherapy + | NCT02743494 | 2016 Active but not recruiting |
|                          | surgery              |               |                 |
|                          | + Rucaparib          | NCT03995017 | 2019 Recruiting |
|                          | + Mogamulizumab      | NCT02946671 | 2016 Completed in 2020, but no results published |
|                          |                     | NCT02476123 | 2015 Completed in 2020, but no results published |
|                          | Radiotherapy         | NCT03544736 | 2018 Recruiting |
|                          | Chemoradiotherapy    | NCT02844075 | 2016 Active, but not recruiting |
|                          | Chemoradiotherapy    | NCT03064490 | 2017 Recruiting |
|                          | Chemoradiotherapy    | NCT03322267 | 2017 Recruiting |
|                          | Chemoradiotherapy    | NCT03792347 | 2019 Active, but not recruiting |
|                          | Chemoradiotherapy +  | NCT02998268 | 2016 Active, but not recruiting |
|                          | chemotherapy         |               |                 |
|                          | After chemoradiotherapy + | NCT02844075 | 2016 Active but not recruiting |
|                          | surgery              |               |                 |
|                          | After chemoradiotherapy and surgery | NCT03322267 | 2017 Recruiting |
|                          | Chemotherapy         | NCT02954536 | 2016 Recruiting |
|                          | + Trastuzumab        |               |                 |
|                          | + Epacadostat        | NCT03592407 | 2018 Withdrawn due to safety concerns |
|                          | Chemotherapy         | NCT03189719 | 2017 Active, but not recruiting |
|                          | Chemotherapy         | NCT03881111 | 2019 Withdrawn due to protocol amendment |
|                          | Chemotherapy         | NCT04437212 | 2020 Recruiting |
|                          | Radiotherapy         | NCT02830594 | 2016 Active, but not recruiting |
|                          | Brachytherapy: 16Gy/2F | NCT02642809 | 2015 Active, but not recruiting |
|                          | DKN-01               | NCT02013154 | 2013 Active, but not recruiting |
|                          | INCAGN01876 +        | NCT03277352 | 2017 Completed in 2020, but no results published |
|                          | Epacadostat          |               |                 |
Table I. Continued.

| Immuno‑therapeutic option | Stage of development | Combined with | ClinicalTrials.gov identifier | Start time | Current status |
|----------------------------|----------------------|---------------|-------------------------------|------------|---------------|
| Immune checkpoint inhibitor treatment |                       |               |                               |            |               |
| Phase 2                 | Tadalafil            | NCT03993353   | 2019 Recruiting               |            |               |
| Phase 2                 | + CRS‑207            | NCT03122548   | 2019 Terminated because of low enrolment and lack of clinical activity in other CRS‑207 studies |            |               |
| Camrelizumab Phase 2    | Radiotherapy         | NCT03200691   | 2017 Recruiting               |            |               |
| Phase 2                 | Radiotherapy         | NCT03187314   | 2017 Recruiting               |            |               |
| Phase 2                 | Chemotherapy         | NCT03917966   | 2019 Not yet recruiting       |            |               |
| Phase 3                 | Chemotherapy         | NCT03691090   | 2018 Recruiting               |            |               |
| Phase 2                 | Chemoradiotherapy    | NCT04390945   | 2020 Recruiting               |            |               |
| Phase 3                 | Chemoradiotherapy    | NCT04426955   | 2020 Recruiting               |            |               |
| Phase 3                 | Chemoradiotherapy    | NCT04404491   | 2020 Recruiting               |            |               |
| Phase 2                 | After chemoradiotherapy | NCT03817658 | 2019 Not yet recruiting       |            |               |
| Phase 1                 | After chemoradiotherapy | NCT03985046 | 2019 Recruiting               |            |               |
| Phase 2                 | After chemoradiotherapy | NCT04286958 | 2020 Recruiting               |            |               |
| Phase 2                 | Apatinib             | NCT03736863   | 2019 Not yet recruiting       |            |               |
| Phase 2                 | Apatinib + chemotherapy | NCT03603756 | 2018 Recruiting               |            |               |
| Phase 2                 | Nimotuzumab          | NCT03766178   | 2018 Recruiting               |            |               |
| Sintilimab Phase 1/2    | Chemotherapy         | NCT03946969   | 2019 Recruiting               |            |               |
| Phase 3                 | Chemotherapy         | NCT03748134   | 2018 Recruiting               |            |               |
| Phase 1                 | Chemoradiotherapy    | NCT03940001   | 2019 Recruiting               |            |               |
| Spartalizumab Phase 1   | LGK974               | NCT01351103   | 2011 Recruiting               |            |               |
| Phase 1/2               | LAG525               | NCT02460224   | 2015 Active, but not recruiting |            |               |
| Phase 2                 | LAG525               | NCT03365791   | 2017 Active, but not recruiting |            |               |
| Phase 2                 | MCS1110              | NCT03785496   | 2018 Active, but not recruiting |            |               |
| Phase 1                 | TNO155               | NCT04000529   | 2019 Recruiting               |            |               |
| Tislelizumab Phase 2    | Chemotherapy         | NCT03469557   | 2018 Active, but not recruiting |            |               |
| Phase 3                 | Chemotherapy         | NCT03783442   | 2018 Recruiting               |            |               |
| Phase 3                 | Chemoradiotherapy    | NCT03957590   | 2019 Recruiting               |            |               |
| Toripalimab Phase 2     | Chemotherapy         | NCT03985670   | 2019 Recruiting               |            |               |
| Phase 3                 | Chemotherapy         | NCT03829969   | 2019 Recruiting               |            |               |
| Phase 2                 | Chemoradiotherapy    | NCT04006041   | 2019 Recruiting               |            |               |
| Phase 2                 | Chemoradiotherapy    | NCT04005170   | 2019 Recruiting               |            |               |
| Phase 2                 | Chemoradiotherapy    | NCT04084158   | 2019 Recruiting               |            |               |
| Phase 2                 | Chemoradiotherapy    | NCT04177875   | 2019 Recruiting               |            |               |
| Phase 2                 | After Chemoradiotherapy + surgery | NCT04437212 | 2020 Recruiting               |            |               |
| HLX‑10 Phase 3          | Chemotherapy         | NCT03958890   | 2019 Recruiting               |            |               |
| Avelumab Phase 1/2      | Chemoradiotherapy    | NCT03490292   | 2018 Recruiting               |            |               |
| Phase 2                 | Chemoradiotherapy    | NCT03800953   | 2019 Not yet recruiting       |            |               |
| Phase 2                 | Chemotherapy before surgery | NCT03399071 | 2018 Recruiting               |            |               |
| Atezolizumab Phase 2     | Chemoradiotherapy    | NCT03087864   | 2017 Completed in 2020, but no results published |            |               |
| Phase 1                 | Chemoradiotherapy    | NCT03784326   | 2018 Recruiting               |            |               |
| Phase 2                 | Chemotherapy         | NCT03448835   | 2018 Recruiting               |            |               |
| Phase 1/2               | Cabozantinib         | NCT03170960   | 2017 Recruiting               |            |               |
| Phase 1/2               | KY1044               | NCT03829501   | 2019 Recruiting               |            |               |
| Phase 1/2               | DKN‑01               | NCT04166721   | 2019 Recruiting               |            |               |
Table I. Continued.

| Immunotherapeutic option         | Stage of development | Combined with                      | ClinicalTrials.gov identifier | Start time | Current status          |
|---------------------------------|----------------------|------------------------------------|-------------------------------|------------|-------------------------|
| Immune checkpoint inhibitor treatment |                      |                                    |                               |            |                         |
| Durvalumab                      | Phase 2              | Chemoradiotherapy                  | NCT02962063                   | 2016       | Recruiting              |
|                                 | Phase 2              | Chemoradiotherapy                  | NCT03777813                   | 2018       | Recruiting              |
|                                 | Phase 2              | Chemoradiotherapy + chemotherapy   | NCT02735239                   | 2016       | Active but not recruiting |
|                                 | Phase 2              | After chemoradiotherapy            | NCT04054518                   | 2019       | Not yet recruiting      |
|                                 | Phase 2              | After chemoradiotherapy + surgery  | NCT02639065                   | 2015       | Active but not recruiting |
|                                 | Phase 2              | After chemoradiotherapy + surgery  | NCT02520453                   | 2015       | Active but not recruiting |
|                                 | Phase 2              | Chemoradiotherapy + Tremelimumab   | NCT03377400                   | 2017       | Active but not recruiting |
|                                 | Phase 1              | Chemotherapy + Tremelimumab        | NCT02658214                   | 2013       | Active but not recruiting |
|                                 | Phase 2              | Tremelimumab                       | NCT03292250                   | 2017       | Recruiting              |
|                                 | Phase 2              | Tremelimumab                       | NCT03982173                   | 2019       | Not yet recruiting      |
|                                 | Phase 2              | Tremelimumab + surgery             | NCT04159974                   | 2019       | Recruiting              |
|                                 | Phase 1/2             | Tremelimumab + SBRT                | NCT03212469                   | 2017       | Recruiting              |
| SHR-1316 Phase 2                | Chemotherapy         | NCT03732508                        | 2018                           | Recruiting |
|                                 | Nimotuzumab          | NCT03766178                        | 2019                           | Not yet recruiting |
| Adoptive T-cell therapy         |                      |                                    |                               |            |                         |
| Phase 1                          | HER2Bi-armed T-cells + IL-2 | NCT02662348                        | 2016                           | Unknown    |
| Phase 1/2                        | CAR-T combined with PD-1 knockout T-cells | NCT03706326                      | 2018                           | Recruiting |
| Phase 1                          | CAR-T combined with CadVEC (oncolytic adenovirus) | NCT03740256                      | 2018                           | Recruiting |
| Phase 1                          | TCR-T + Cyclophosphamide + Fludarabine | NCT02869217                      | 2016                           | Recruiting |
| Phase 1                          | TCR-T + + Fludarabine Cyclophosphamide | NCT02366546                      | 2015                           | Active but not recruiting |
| Phase 1                          | TCR-T + + Fludarabine Cyclophosphamide | NCT02096614                      | 2017                           | Unknown    |
| Phase 1                          | TCR-T + Radiotherapy  | NCT03132922                        | 2017                           | Recruiting |
| Phase 1                          | TCR-T + Trastuzumab   | NCT03680560                        | 2018                           | Suspended by the sponsor |
| Peptide vaccine                  |                      |                                    |                               |            |                         |
| Phase 1                          | + Chemotherapy       | NCT00632333                        | 2011                           | Unknown    |
| Phase 2                          | + Toll-like receptor 9 agonist | NCT00669292                      | 2010                           | Unknown    |
| Phase 2                          | + Granulocyte-macrophage colony stimulating factor | NCT00012246                      | 2013                           | Terminated without any published results |
is expressed, immunological tolerance exists and only in the case of a PD-1+ tumour microenvironment containing CD4+ T-cells an adoptive immune resistance is present that is most likely to respond to immune checkpoint inhibitor therapy (79).

5. Adoptive T-cell therapy

Adoptive T-cell therapy is a personalized approach of immunotherapy. T-cells are collected from the tumour or peripheral blood of a patient and the isolated T-cells are stimulated in vitro with IL-2. After this ex-vivo expansion, the cancer patient receives his own autologous immune cells as an infusion (80). In addition, T-cells can be also genetically modified after collection from the patient either by introducing chimeric antigen receptor (CAR T-cells) or transducing antigen-specific TCR cells (TCR T-cells). In all cases, the expanded or modified T-cells exert an improved tumour-specific immunity (81-83).

In several trials, a regression of tumours has been demonstrated following persistent adoptive T-cell therapy (84,85). In a first clinical trial based on adoptive T-cell therapy for patients with recurrent or advanced oesophageal cancer, the patients received (on a fortnight basis) activated T-cells administered into primary tumours or metastatic lymph nodes; this therapy was found to be safe and in one third of the patients, a significant tumour regression was observed (86). In another study, based on TCR T-cells, oesophageal cancer patients with minimal lesions survived >27 months; nevertheless, after 2 months of treatment, several patients exhibited tumour progression even if the autologous T-cells persist for a long period of time; therefore, TCR T-cell therapy appears to have a benefit only for oesophageal cancer patients with minimal lesions (87).

6. Peptide vaccine

Peptide vaccines are therapeutic cancer vaccines which aim to increase immunogenic cancer-specific antigens, leading to the activation of cancer antigen-specific T-cells in vivo (59,76,88). For the successful use of peptide vaccines, the characterization of tumour-specific T-cells and the use of immunogenic tumour-associated antigens are a prerequisite (89). As tumour-associated antigens, either recombinant short peptides, whole-cell tumour lysates or full-length proteins can be used (90,91). The length of the used peptide has at least in part an influence on the efficiency of the immune response (92). It has been well-established that short peptides composed of 8-11 amino acids induce major histocompatibility complex (MHC) class-I-restricted antigen-specific CD8+ T-cell reaction via direct binding to human leukocyte antigen (HLA)-I molecules (93). By contrast, longer peptides (25-50 amino acids) are usually presented by MHC class-I and class-II molecules on antigen-presenting cells to CD8+ or CD4+ T-cell, respectively (94). This results in a broader and longer lasting immune response by generating cytotoxic T-lymphocytes as well as long-living memory CD8+ T-cells (95).

In a modified approach, dendritic cells isolated from the peripheral blood of a cancer patient are presented to tumour-associated antigens ex vivo and after loading with the antigens the dendritic cells, are re-injected into patients (91,96). This strategy was evaluated in a pre-clinical study as possible novel treatment option for oesophageal tumours (97). Dendritic cells from oesophageal cancer patients have been pulsed with Wilms’ tumour 1 peptide ex vivo and used as a vaccine. The patients were treated in parallel with the chemotherapeutic agent, picibanil. In this exploratory study, 15 patients were included; the median progression-free survival and overall survival were 4.1 and 7.0 months, respectively. This treatment was well-tolerated and no severe adverse events related to the vaccinations were observed (97). Based on this promising result, a phase II clinical trial is in preparation.

Even with the first-generation of peptide vaccines which have been based on highly expressed non-mutant tumour-associated antigens of tumour cells [such as melanoma antigen gene (MAGE) and New York oesophageal squamous cell carcinoma-1 (NY-ESO-1) proteins] an immune response was induced and led to clinical positive effect (98-100). The advantage of these peptides is that they are only expressed in male

---

Table I. continued.

| Immuno-therapeutic option          | Stage of development | Combined with                                     | ClinicalTrials.gov identifier | Start time | Current status  |
|------------------------------------|----------------------|--------------------------------------------------|-------------------------------|------------|----------------|
| Oncolytic virus                    |                      |                                                  |                               |            |                |
| Oncolytic measles virus            | Phase 1              | +5-Fluorocytosine + anti-PD-1 checkpoint inhibitor| NCT04195373                  | 2020       | Withdrawn      |
| Oncolytic adenovirus               | Phase 1              | CAVVEC combined with CAR-T                        | NCT03740256                  | 2018       | Recruiting     |
|                                   | Phase 1              | Telomelysin + radiotherapy                        | NCT03213054                  | 2017       | Recruiting     |
|                                   | Phase 2              | Telomelysin + Pembrolizumab                       | NCT03921021                  | 2019       | Recruiting     |

ClinicalTrials.gov was accessed in November, 2020.
germ-line cells and placenta under physiological conditions; however, a number of tumours, among these oesophageal cancer, express these proteins as well. Therefore, they represent very promising targets for cancer immunotherapy (101-103).

The second-generation of peptide vaccines is an effort for a more personalized medicine with the aim of targeting mutated antigens that are patient-specific. In this approach, mutations which have been accumulated during tumour development are the basis for the vaccine generation (104). In the context of oesophageal cancer, a large number of genetic mutations are present which result in specific neo-antigens (105). The main challenge is to identify mutated epitopes derived from tumour neo-antigens for developing a patient-specific vaccine (106,107). The vaccine peptides are patient-specific and they differ completely among patients. Therefore, batch production will not be possible and it will never become a conventional drug (104). The advantage is that neo-antigen vaccines result in a potent T-cell response and induce a new population of specific T-cells in cancer patients that are able to kill cancer cells without damaging healthy tissues (104,108,109). Furthermore, pre-clinical trials are forthcoming with an aim to induce the T-cell response by ribonucleic acid (RNA)-based vaccine coding for multiple neo-epitopes (110). Another novel strategy combines the use of long-peptide vaccines with checkpoint inhibitor administration (111). The aim in both cases, is to increase the repertoire of CD8⁺ and CD4⁺ T-cell directed against the tumour. These personalized approaches have the potential to offer novel therapeutic options with high specificity and low toxicity for cancer patients who are resistant to current therapies.

Peptide vaccines have been used in several clinical trials in patients with oesophageal squamous carcinoma. Different peptides have been administered simultaneously to patients, which resulted in a significant induced CD8⁺ T-cell response. Clinical benefit, as well as an increased overall survival was observed in the majority of patients (112,113). Peptide vaccinations can be combined with other therapeutic options in patients with oesophageal tumours. One example is the use of a peptide vaccine to suppress the recurrence of oesophageal cancer following curative resection. In a previous study, the
5-year relapse-free survival of oesophageal cancer patients was 44.6% in patients that received the vaccination compared to the ones that did not receive the vaccination (31.6% relapse-free survival) (114). Of special interest is the peptide vaccine, S-588410, which is composed of 5 HLA-A^*2402-restricted epitope peptides derived from the onco-antigens, DEPDC1, MPHOSPH1, URLC10, CDCA1 and KOC1. All these antigens are up-regulated in the context of oesophageal cancer (115,116). In previous studies, it was proven that each of these 5 peptides has the capacity to induce a peptide-specific activation of CD8^+ T-cells in different tumours, among these oesophageal cancer (112,113,117,118). In an exploratory study based on 15 patients with oesophageal tumours, an increased immune response in tumour tissue was observed following vaccination with S-588410. Following a median of 5 injections of S-588410, peptide-specific CD8^+ T-cells for all peptides included in this vaccination were induced in all patients. The number of functional T-lymphocytes (CD8^+ and CD4^+ T-cells) was found to be increased in blood, as well as in tumour biopsies. In parallel, a higher PD-L1 expression in the tumour microenvironment was observed (115). Most probably, the increased PD-L1 expression was related to interferon (IFN)-γ produced by infiltrated CD8^+ T-cells into the tumour area. The accumulation of effective T-cells and IFN-γ production in the tumour microenvironment most probably favour the change from an immune ‘desert’ into an immune-inflamed tumour microenvironment (93). It is tempting to speculate about the therapeutic potential of combining peptide vaccines, such as S-588410 with immune-checkpoint inhibitors in patients with oesophageal cancer (54,79).

7. Oncolytic viruses

Oncolytic virus therapy is still in its infancy, but it has already proven its potential. In general, oncolytic viruses infect and replicate selectively in tumour cells and induce tumour cell lysis (119,120). Talimogene laherparepvec is the first FDA-approved oncolytic viral therapy for the treatment of patients with advanced melanoma (121). Recently, the efficacy of a telomerase-specific oncolytic virus (telomelysin OBP-301) in combination with radiotherapy was investigated in a Phase I/II study for the treatment of elderly patients with oesophageal squamous cell carcinoma. According to the first results, this viral therapy was well-tolerated and demonstrated efficient tumour regression (122,123). Based on this success, several other clinical trials with various oncolytic viruses for the treatment of patients with oesophageal cancer are ongoing (Table I).

8. Conclusion and perspectives

In oesophageal cancer, as in most other tumour diseases, the therapeutic options are limited and therapeutic success is only achieved for a short period of time before resistance appears. Therefore, novel therapeutic options, such as the addition of immunotherapy to the treatment of tumours are an urgent need. Albeit some success of immunotherapy in oesophageal cancer treatment and the approval of pembrolizumab and nivolumab by the FDA, it is noteworthy to mention that immunotherapy is often associated with severe toxic side-effects; the most frequent ones are cutaneous, gastrointestinal, endocrine and hepatic toxicity. Therefore, a careful monitoring and follow-up of patients under immunotherapy is required and if necessary, the patient must receive effective measures to manage the side-effects. An advantage for patients with oesophageal cancer could be a combination of immunotherapy with surgery, chemotherapy and radiotherapy. Recently, the advantage from radiotherapy in parallel with immune checkpoint inhibitor treatment was already demonstrated (124).

A prerequisite for improving the success and efficiency of immunotherapy is the knowledge about robust biomarkers predicting clinical benefit before treatment and enabling stratification of oesophageal cancer patients in such a manner that the best possible immunotherapy can be applied to each patient. One possibility could be the multiplexed immunohistochemical staining of adaptive immune (CD3, CD4, CD8 and CD45RO) and immune checkpoint biomarkers [inducible T-cell costimulatory molecule (ICOS), indoleamine-2,3-dioxygenase-1 (IDO-1), PD-L1 and PD-1] in combination with digital pathology quantitation (125). Furthermore, it is well-established that immunotherapies are resulting in an increased tumour burden and/or emergence of new tumour lesions in the short-term. Therefore, the currently used evaluation system for therapeutically success is most probably not applicable for immunotherapies; thus, it may be prudent to consider a different system for this novel type of therapy.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

JCH, AL and NV were involved in the conceptualization of the study. JCH, MG, MR and AL were involved in the writing and preparation of the original draft. JCH, NV, MBM and AFO were involved in the writing, reviewing and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

NV received speaker honorarium from the companies, Bayer, Eli-Lilly, Pfizer and Merck. The funders had no role in the design of the study; in the collection, analyses, or interpretation
of data; in the writing of the manuscript, or in the decision to publish the results. All other authors (AL, MR, MG, MM, AFO and JCH) declare that they have no competing interests.

References

1. de Vos-Geelen J, Hoebers FJP, Geurts SME, Hoeben A, de Greef BTA, Voncken FEM, Bogers JHA, Brinkman PM, Muijs CKT, de Jong MA, et al: A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol 59: 895-903, 2020.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Torre LA, et al: Global cancer statistics. CA Cancer J Clin 68: 7-30, 2018.

3. Sang Y, Lu Y, Lagergren P and Lagergren J: Risk factors for esophageal cancer development. Asian Pac J Cancer Prev 12: 2461-2466, 2011.

4. Bottiroli V, Bovero E and Iaquinta G: Characterization of acid and alkaline reflux in patients with Barrett's esophagus. G.O.S.P.E. Operative Group for the study of Esophageal Precancer. Dis Esophagus 10: 16-22; discussion 22-3, 1997.

5. Fassan M, Realdon S, Ciaccone L, Hahne JC, Munari G, Guzzardo V, Arcidiacono D, Lampis A, Brigonda S, Dal Santo L, et al: Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. Pathol Res Pract 216: 152907, 2020.

6. Lin J, Zeng R, Cao W, Luo R, Chen J and Lin Y: Hot beverage and food intake and esophageal cancer in southern China. Asian Pac J Cancer Prev 12: 2189-2192, 2011.

7. Fassan M, Rodriguez-Martinez B and Lengel E: Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831: 1533-1541, 2013.

8. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218, 2013.

9. Ratti M, Lampis A, Hahne JC, Passalacqua R and Valieri N: Microsatellite instability in gastric cancer: Molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci 75: 4151-4162, 2018.

10. Lin Z, Karamakheva TA, Hicks PD, Bass AJ and Rustgi AK: The tumor microenvironment in esophageal cancer. Oncogene 35: 5337-5349, 2016.

11. Ammannegari N and Atasoy A: Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. J Gastrointest Oncol 9: 196-207, 2018.

12. DT, Uram JN, Wang S, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 Blockade in tumors with Mismatch-Repair deficiency. N Engl J Med 372: 2509-2520, 2015.

13. Kim WK, Park M, Park M, Kim YJ, Shin N, Kim HK, You K and Kim H: Identification and selective degradation of neoplastic tumor microenvironment in esophageal cancer: Pathobiological and clinical perspectives, and new treatment approaches. Target Oncol 11: 593-603, 2016.

14. Li P, Xu W, Liu F, Zhu H, Zhang L, Ding Z, Liang H and Song J: The emerging roles of IDO2 in cancer and its potential as a therapeutic target. Biomed Pharmacother 137: 111295, 2021.

15. Zhou H, Jiang M, Yuan H, Ni W and Tai G: Dual roles of IdO2 in cancer: The emerging roles of IdO2 in cancer and its potential as a therapeutic target. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol 59: 895-903, 2020.

16. Lagergren J and Lagergren P: Recent developments in esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 6: 112-120, 2014.

17. Bartley AN, Washington MK, Ventura CB, Israelia N, Colasacco C, Benson AB III, Carrato A, Gulley ML, Jain D, Kallan S, et al: HER2 testing and decision making in gastroesophageal adenocarcinoma: Guideline from the college of American pathologists, American society for clinical pathology, and American society of clinical oncology. Arch Pathol Lab Med 140: 1345-1363, 2016.

18. Bang YJ, van Cutsem E, Feyerisenova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.

19. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D and ESMO Guidelines Committee: Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27 (Suppl 5): v50-v57, 2016.

20. Le Bras GF, Farooq MH, Falk GW and Andl CD: Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmaco Res 13( Pt A): 236-244, 2016.

21. Short MW, Burgers KG and Fry VT: Esophageal cancer. Am Fam Physician 95: 22-28, 2017.

22. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al: Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society. Part 2: Esophagus 16: 25-43, 2019.

23. Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, Wang M, Min L, Liu X, Zhang X, et al: The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: A meta-analysis of clinical studies. Drug Des Devel Ther 13: 539-553, 2019.
42. Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, et al: Immune evasion mediated by PD-L1 on glioblastoma-derived cell lines. Nat Sci Adv 4: eabc3676, 2018.

43. Theodoraki MN, Yerennis S, Hoffmann TK, Gooding WE and Whiteside TL: Clinical significance of PD-L1(+)/exosomes in plasma of head and neck cancer patients. Clin Cancer Res 24: 896-905, 2018.

44. Corthay A: How do regulatory T cells work? Scand J Immunol 70: 226-336, 2009.

45. Romano M, Fanelli G, Albany CJ, Giganti G and Lombardi G: Past, present, and future of regulatory T Cell therapy in transplantation and autoimmunity. Front Immunol 10: 43, 2019.

46. Togashi Y, Shiitara K and Nishikawa H: Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat Rev Clin Oncol 16: 356-371, 2019.

47. Engel JB, Honig A, Kapp M, Hahne Jc, Meyer SR, di etl J and Togashi Y, Shitara K and Nishikawa H: Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat Rev Immunol 9: 162-174, 2009.

48. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 19: 162-174, 2009.

49. Gabrilovich DI: Myeloid-Derived suppressor cells. Cancer Immunol Res 5: 3-8, 2017.

50. Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sassetti Kc, Beatty GL, Gabrilovich DI and Rustgi AK: CD38−/M-DMD expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight 3: e97022, 2018.

51. Shi T, Ma Y, Yu L, Jiang J, Shen S, Hou Y and Wang T: Cancer immunotherapy: A focus on the regulation of immune checkpoint inhibitors in melanoma. Int J Mol Sci 19: 1389, 2018.

52. Kim ES, Kim JE, Patel MA, Mangavarti A, Ruzvejk J and Lim M: Immune checkpoint modulators: An emerging anti-glioma armamentarium. J Immunol Res 2016: 4633607, 2016.

53. Vivaldi C, Catanesi S, Massa V, Pecora I, Santi S, Lencioni M, Vasile E, Falcone A and Fornaro L: Immune checkpoint blockade: A common denominator approach to cancer therapy. Int J Mol Sci 19: 2018.

54. Segerer SE: Mechanism of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet 289: 141-147, 2018.

55. Mimura K, Yamada L, Ujiie d, Hayase S, Tada T, Hanayama H, Wittig S, Chuaqui R, Stancu G, Stajic Z, et al: Increased Tim-3 in patients with metastatic ovarian cancer. J Immunol 185: 2130-2139, 2010.

56. Brahmer JR, Hwu WJ, Topalian SL, Hamid O, Drakopoulos P, Ribas A, Wolchok JD, Pardoll DM, Piha‑Paul SA, Falchook GS, Robert C, Lebleu B, Restifo NP, Rosenberg SA and Restifo NP: Adoptive cell transfer as person — oncology. J Thorac Oncol 10: 1339, 2015.

57. Ota H, Umegaki H, Yabuta T, Nakazawa Y, Inoue Y, Koyama K, Kubo K, Shimizu M, Hamada T, Horiuchi Y, et al: Evaluation of PD-L1 expression as a predictive biomarker in esophageal cancer. Jpn J Clin Oncol 41 (Suppl 5): S3-S13, 2014.

58. Patel SP and Kurzrock R: PD-L1 expression as a predictive biomarker in esophageal squamous cell carcinoma. Expert Rev Mol Med 16: 1-25, 2014.

59. Darvin P, Toor SM, Sasidharan Nair V and Elkord E: Immune checkpoint inhibitors: A focus on the regulation of immune checkpoint inhibitors in melanoma. Int J Mol Sci 19: 1389, 2018.

60. Simonsen L, Kragh-Sorensen P, Poulsen MA, Aaes‑Iversen S, Hansen HH, Poulsen MS, Christiansen JS, Helin TK, Poulsen JN, Pedersen JH, et al: Effect of IL-18 on the expansion and phenotype of human natural killer cells: Application to cancer immunotherapy. Int J Biol Sci 14: 331-340, 2018.

61. Patel SP and Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14: 847-856, 2015.

62. Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Hisamatsu T, Miyamoto T, Uchida J, et al: Anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol 36: 61-67, 2018.

63. Harmanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al: Safety and antitumor activity of Anti-PD-1 Antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33: 4015-4022, 2015.

64. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al: Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20: 1506-1517, 2019.

65. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV and Dhodapkar KM: Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194: 950-959, 2015.

66. Tanaka T, Nakamura J and Nishio H: Promising immunotherapies for esophageal cancer. Expert Opin Biol Ther 17: 723-733, 2017.

67. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, et al: CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36: 2836-2844, 2018.

68. Zhao Y, Yang W, Huang Y, Cui R, Li X and Li B: Evolving roles of PD-L1 as cancer therapeutics. J Hematol Oncol 12: 92, 2019.

69. Darvin P, Toor SM, Sasidharan Nair V and Elkord E: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Expert Rev Mol Med 50: 1-11, 2018.

70. Rosenberg SA and Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348: 62-68, 2015.

71. Alsina M, Moehler M and Lorenzen S: Immunotherapy of esophageal cancer: Current status, many trials and innovative strategies. Oncol Res Treat 41: 266-271, 2018.

72. Miliotou AN and Papadopoulos LC: CAR-T cell Therapy: A New Era in cancer immunotherapy. Curr Pharm Biotechnol 19: 5-18, 2018.

73. Walseng E, Koksal H, Sektioglu IM, Fåne A, Skorstad G, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, et al: Increased Tim-3 (4) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother 5467: 1673-1683, 2018.

74. Walseng E, Koksal H, Sektioglu IM, Fåne A, Skorstad G, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, et al: Increased Tim-3 (4) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother 5467: 1673-1683, 2018.
85. Dudley ME, Yang JC, Sherry R, Hughes MS, Royall R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al.: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemotherapy preparative regimens. J Clin Oncol 26: 5233-5239, 2008.

86. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirouzu K and Itoh K: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 20: 2268-2277, 2014.

87. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al.: Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21: 2276-2287, 2015.

88. Li W, Joshi MD, Singhania S, Ramsey KH and Murthy AK: Peptide vaccine: Progress and challenges. Vaccines (Basel) 2: 513-534, 2014.

89. Masopust D and Schenkel JM: The integration of T cell migration and function. Nat Rev Immunol 13: 309-320, 2013.

90. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G and Galluzzi L: Trial Watch: Peptide vaccines in cancer therapy. Oncology 2: e26621, 2015.

91. Tacken PJ, de Vries IJ, Torensma R and Figdor CG: Dendritic-cell Blander JM: Regulation of the cell biology of antigen processing. Annu Rev Immunol 36: 717-753, 2018.

92. Quillot T, Krepela SI and Ossendorf F: Approaches to improve chemically defined synthetic peptide vaccines. Front Immunol 9: 884, 2018.

93. Chen DS and Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature 541: 321-330, 2017.

94. Fendler J, Mohr K and Wölfle J: Antigen presentation of the generation of antigen cross-presentation. Annu Rev Immunol 36: 633, 2018.

95. Quillot T, Krepela SI and Ossendorf F: Approaches to improve chemically defined synthetic peptide vaccines. Front Immunol 9: 884, 2018.

96. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Tacken PJ, de Vries IJ, Torensma R and Figdor CG: Dendritic-cell Blander JM: Regulation of the cell biology of antigen processing. Annu Rev Immunol 36: 717-753, 2018.

97. Kono K and Schenkel JM: The integration of T cell migration and function. Nat Rev Immunol 13: 309-320, 2013.

98. Tacken PJ, de Vries IJ, Torensma R and Figdor CG: Dendritic-cell Blander JM: Regulation of the cell biology of antigen processing. Annu Rev Immunol 36: 717-753, 2018.

99. Tacken PJ, de Vries IJ, Torensma R and Figdor CG: Dendritic-cell Blander JM: Regulation of the cell biology of antigen processing. Annu Rev Immunol 36: 717-753, 2018.

100. Tacken PJ, de Vries IJ, Torensma R and Figdor CG: Dendritic-cell Blander JM: Regulation of the cell biology of antigen processing. Annu Rev Immunol 36: 717-753, 2018.

Attribution 4.0 International (CC BY 4.0) License.